Navigation Links
China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification

HARBIN, China, Sept. 19 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it has successfully completed the first phase of examinations for the Conformite Europeenne (CE) certification, or CE mark, which indicates that a company's products have met rigorous testing and safety standards and are approved for sale within the European Union (EU).

In order to sell products throughout the EU, China Sky one submitted an application for CE certification in May, 2008, to Heilongjiang Import-Export Commodities Inspection and Quarantine (SAIECIQ) Bureau Technology Center, the CE certification's agency in China. Experts from the center spent three months reviewing and examining manufacturing materials, on-site facilities, and product samples. It was determined that China Sky One Medical's facilities, quality control systems, and products met CE certification standards. The Company is currently working on the second phase of the CE certification examination and estimates that it could begin to export products to the EU with the CE mark starting in 2008. (For more information visit )

"Receiving the CE certification will be a passport to importing our drugs into the EU market and also attest to the high quality of our products and our manufacturing standards," said Mr. Yan-qing Liu, Chairman, CEO and President of China Sky One Medical. "Affixing the CE mark to our products will ensure that they meet all of the applicable regulatory and safety requirements within the EU."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio- Engineering Company Limited, and Heilongjiang Tianlong Pharmaceutical, Inc., the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

China Sky One Medical, Inc.

Mr. Yu-bo Hao, Board Secretary

Tel: +86-0451-5399-4069


Investor Relations Contact:

CCG Investor Relations

Mr. Crocker Coulson, President

Tel: +1-646-213-1915


Mr. Richard Micchelli, Financial Writer

Tel: +1-646-454-4516



SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40%
2. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
3. China Biopharma Effects 1 for 100 Reverse Stock Split
4. China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company
5. China Yingxia International, Inc. Appoints New Vice President of Finance
6. China-Biotics, Inc. Provides Update on Construction of New Manufacturing Facility
7. China Biologic Products to Present at the SIG Beijing Management Summit
8. China Biologics Production Facility Renews GMP Certification
9. China Bio Energy Holdings Group Announces Participation in the Susquehanna Second Annual Beijing Management Summit
10. Plexus Announces Expansion in Hangzhou, China
11. China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market
Post Your Comments:
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... 2015 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... fireside chat discussion at the Piper Jaffray 27th Annual ... The discussion is scheduled for Wednesday, December 2, at ... A replay will be available for 14 days after ... Julie NormartVP, Corporate Communications and Business Development , BrewLife(858) ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015 ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... -- Daon, a global leader in mobile biometric authentication ... version of its IdentityX Platform , IdentityX v4.0. ... have already installed IdentityX v4.0 and are seeing ... UAF certified server component as an option and ... These customers include some of the largest and most ...
Breaking Biology News(10 mins):